All In MedTech

Device Trial Radar · NCT07208604

Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients in the Philippines

Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients: An Open Label, Phase I Study of the TECLens Corneal Crosslinking System for Correction of Refractive Error in Adult Patients Before and After the Onset of Presbyopia

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Oct 11, 2025

Primary completion

May 2027

Study completion Aug 2027

Sponsor

Lead sponsor
TECLens, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 6, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 25 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the TECLens on-eye corneal crosslinking system can safely reduce refractive error (nearsightedness or farsightedness) in adults aged 25 to 75, including people who have reached the age when reading glasses are usually needed (presbyopia). The main questions it aims to answer are: Is the treatment safe for the cornea, including the cells that keep it clear? Does the treated eye's prescription change as planned, reaching within 0.75 diopters of the target 3 months after treatment? Participants will have one eye treated once with riboflavin (vitamin B2) eye drops and low-energy ultraviolet light delivered through a special contact lens. They will then return for eye exams 1 day, 1 week, and 1, 2, 3 and 6 months after treatment.

Conditions

  • Presbyopia
  • Refractive Errors
  • Myopia
  • Hyperopia

Interventions

  • TECLens CXLens Crosslinking SystemDevice

    Investigational corneal crosslinking system that uses riboflavin and ultraviolet light, delivered through a scleral contact lens platform, to change the shape and refractive power of the cornea according to a treatment plan personalized for each eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Treated Eyes With Manifest Refraction Within 0.75 D of the Planned Target RefractionTime frame: 3 months after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asian Eye Institute

    Makati City, National Capital Region, Philippines · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.